Business UpdateMay 7, 2026, 04:16 PM
Aligos Therapeutics Gets Fast Track, $25M Upfront for HBV Drug
AI Summary
Aligos Therapeutics reported its first quarter 2026 financial results and significant business progress. The company received FDA Fast Track Designation for pevifoscorvir sodium for chronic HBV infection and entered an exclusive licensing deal with Amoytop for Greater China, including a $25 million upfront payment. The Phase 2 B-SUPREME study for pevifoscorvir sodium will continue after a positive interim analysis, with the DSMB recommending increased participant enrollment. For Q1 2026, Aligos reported a net loss of $23.0 million, with cash, cash equivalents, and investments totaling $54.9 million, expected to fund operations into Q4 2026.
Key Highlights
- Pevifoscorvir sodium received FDA Fast Track Designation for chronic HBV infection.
- Aligos signed an exclusive license deal with Amoytop for pevifoscorvir sodium in Greater China, including a $25M upfront payment.
- The Phase 2 B-SUPREME study's first interim analysis was positive, with the DSMB recommending increasing the HBeAg- cohort to 100 participants.
- Net loss for Q1 2026 was $23.0 million, compared to net income of $43.1 million in Q1 2025.
- Cash, cash equivalents, and investments totaled $54.9 million as of March 31, 2026.
- Research and development expenses increased to $23.4 million in Q1 2026 from $14.5 million in Q1 2025.
- The company expects its cash runway to extend into Q4 2026, inclusive of the $25M upfront payment.